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Pancreatic cancer is a devastating disease in which current therapies are inadequate. Separate lines of research have identiﬁed the
5-lipoxygenase/leukotriene B4 receptor pathway and the PPARγ pathway as potential targets for prevention or treatment of this
disease.LY293111wasoriginallydesignedasapotentleukotrieneB4 receptorantagonistfortreatmentofinﬂammatoryconditions.
LY293111 was also known to have inhibitory eﬀects on 5-lipoxygenase, which is upstream of the production of leukotrienes.
LY293111 was shown to have potent anticancer eﬀects in pancreatic cancer and several other solid malignancies, where it caused
cell cycle arrest and marked apoptosis. Subsequently, it came to light that LY293111 exhibited PPARγ agonist activity in addition
to its eﬀects on the 5-lipoxygenase pathway. This raises the question of which of the two targets is of greatest importance with
regard to the anticancer eﬀects of this agent. The evidence to date is not conclusive, but suggests that the eﬀects of LY293111 may
be mediated by both LTB4 receptors and PPARγ.
Copyright © 2008 Thomas E. Adrian et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Pancreatic Cancer is a devastating disease with more than
80% of all patients presenting with surgically inoperable
tumors. It remains the fourth leading cause of cancer death
in both men and women in the USA. The median survival
is usually less than six months even with the addition of
chemotherapy [1–3]. Surgical resection is the only eﬀective
treatment option, but there are few long-term survivors even
after apparent curative resection [1–3]. Alternative eﬀective
treatment strategies are desperately needed for this disease.
1.1. Fattyacidsandhumancancer
Epidemiological and animal studies show that a high fat
consumption is associated with a higher incidence and
growth of tumors at several speciﬁc organ sites including
breast, pancreas, and prostate [4–11]. Recent studies indicate
that diets containing a high proportion of polyunsatu-
rated omega-6 fatty acids (n-6 FA), such as linoleic acid
(the precursor of arachidonic acid) are associated with
a more advanced disease stage at the time of diagnosis
of several kinds of cancer [4–6, 8, 10, 11]. In contrast,
long-chain n-3 fatty acids, such as docosahexaenoic acid
and eicosapentaenoic acid (EPA) inhibit the growth and
metastasis of several cancers including pancreatic cancer
[7,9].Omega3fattyacidsinhibittumorgrowthbyanumber
of mechanisms including suppression of COX-2 expression
and, for EPA at least, the alternative substrate produces
diﬀerent cyclooxygenase (PGE3) and lipoxygenase (LTB5)
products that have anti-inﬂammatory and anticancer eﬀects.
1.2. Eicosanoidpathways
Arachidonicacidisasubstrateforthreedistinctivelydiﬀerent
enzymatic pathways. Among them, prostaglandin endoper-
oxide synthases (cyclooxygenases) catalyze the committed
step that leads to prostaglandin biosynthesis [12–14]. The
second pathway is the epoxygenase pathway that appears
to have no role in cancer. The third pathway for metabo-
lizing arachidonic acid, the lipoxygenase pathway catalyzes2 PPAR Research
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Figure 1: Immunocytochemistry of PPARγ receptor in normal human pancreas and in a PanIN lesion and a pancreatic cancer. The PPARγ
receptor antibody shows a similar intensity of nuclear staining in normal ducts and in pancreatic cancer cells as well as cells in the PanIN
lesion. In contrast, no staining is seen in normal islets, but nuclear staining is seen in islets from tissue adjacent to a cancer. These pictures
are representative of eight samples of each tissue type. Staining was similar using antibodies from two diﬀerent commercial sources.
the incorporation of one oxygen molecule into polyun-
saturated fatty acids to yield a 1-hydroperoxy-2, 4-trans,
cis-pentadiene product [14–16]. Mammalian lipoxygenases
possess regiospeciﬁcity during interaction with substrate,
and on this basis have been designated as arachidonate
5-, 12-, and 15-lipoxygenase (5-LOX, 12-LOX, and 15-
LOX) [14–16]. The three distinct enzymes insert oxygen at
carbon 5, 12 or, 15 of arachidonic acid, and the primary
product is 5S-, 12S-, or 15S-hydroperoxyeicosatetraenoic
acid (5-, 12-, or 15-HPETE), which can be further reduced
by glutathione peroxidase to hydroxy forms (5-, 12-, 15-
HETE), respectively [14–16]. 5-LOX is noteworthy because
it is the only pathway that can turn arachidonic acid into
leukotrienes [15, 17]. The activity of 5-LOX is dependent
upon a second factor termed 5-LOX-activating protein
(FLAP) [15, 17]. Considerable eﬀort has been expended by
the pharmaceutical industry to produce inhibitors of FLAP,
5-LOX as well as leukotriene antagonists, because the 5-
LOX products, leukotrienes (LTB4,L T C 4,L T D 4,a n dL T E 4)
have been implicated as mediators of inﬂammation and
immediate hypersensitivity reactions, in particular, human
bronchial asthma [18, 19].
1.3. Leukotrienereceptorantagonistsand
thedevelopmentofLY293111
The pharmaceutical industry has focused on several targets
to suppress leukotriene activity in inﬂammatory conditions
such as bronchial asthma [18, 19]. One approach is to
directly inhibit 5-lipoxygenase activity, thereby blocking
secretion of all leukotrienes. The most widely studied clinical
inhibitor of 5-lipoxygenase is zileuton, which inhibits the
active site of 5-lipoxygenase at concentrations that do not
inhibit cyclooxygenase, 12-lipoxygenase, or 15-lipoxygenase
[18–22]. Another avenue to inhibit leukotriene formation
is via blocking FLAP activity, thus preventing cytoplasmic
to membrane translocation and activation of 5-lipoxygenase
[16–18].MK-0591isawidelyused5-lipoxygenase-activating
protein inhibitor for biomedical research [16–18]. Even
though it strongly inhibits 5-lipoxygenase activity and blocks
leukotriene generation, its use in clinic is limited by marked
side eﬀects. The ﬁnal pharmacological approach to block
leukotriene activity is to selectively block the actions of LTB4
or the sulﬁdopeptide leukotrienes using speciﬁc receptor
antagonists.
Several synthetic LTB4 receptor antagonists have been
developed. Early compounds included SC-41930; ONO-
4057, which was orally active; LY223982, a benzophenone
dicarboxylic acid; and LY255283 a hydroxyacetophenone
[23–27].TheselattertwocompoundsfromtheLillyResearch
Laboratories potently block LTB4 binding to its receptors
within the nM range and inhibit the biological functions
of LTB4 in vitro [28, 29]. Unfortunately, they showed poor
oral bioavailability [28]. In 1995, investigators at the Lilly
Research Laboratories reported a new LTB4 antagonist,
LY293111. This compound is a novel derivative of LY255283,
but is orally stable and more potent as an LTB4 receptor
antagonist [28, 29]. Compared with other LTB4 receptor
antagonists, LY293111 is superior at blocking the cellular
functions induced by LTB4 [28, 30].Thomas E. Adrian et al. 3
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Figure 2:ComparisonoftheeﬀectsofdiﬀerentconcentrationsofLY293111andciglitazoneonproliferationoftwohumanpancreaticcancer
cell lines (Panc-1 and S2-013) after 24 and 96 hours of treatment, measured by thymidine incorporation. LY293111 was approximately 50
times more potent than ciglitazone at inhibiting proliferation of both cell lines. Data shown is mean±SEM from four separate experiments.
1.4. Inﬂammation,Cyclooxygenases,
Lipoxygenases,andcancer
Theepidemiological data show aclearandstrong association
between chronic inﬂammatory conditions and cancer devel-
opment, even though the conditions causing inﬂammation
m a yv a r y[ 31–36]. It can be due to chronic infection
caused by a virus, bacteria, or parasite or it may be due
to noninfective, physical, or chemical irritant [31–36]. For
example, chronic infection with the bacterium Helicobacter
pylori causes atrophic gastritis, which can lead to dysplasia
and adenocarcinoma [37]. Hepatitis B and C viruses account
for more than 80% of cases of hepatocellular carcinoma
worldwide [34]. The inﬂammatory bowel diseases, ulcerative
colitis and Crohn’s disease, predispose to the development of
cancers of the large bowel and/or terminal ileum, although
a causative infectious agent has never been conclusively
identiﬁed [38]. For noninfectious inﬂammation, chronic
reﬂux of gastric acid and bile into the distal esophagus causes
chemical injury and on the long-term can lead to Barrett’s
esophagus and eventually to esophageal adenocarcinoma
[35]. Thus it is apparent that chronic inﬂammation is a
common underlying theme in the development of many
diﬀerent malignancies.
Although the mechanisms for the association between
inﬂammation and cancer are not fully understood, growth
factors, cytokines, and chemokines released into inﬂamma-
tory environment are associated with tumor development
andprogression[32,36].Highconcentrationsoffreeradicals
and nitric oxide can induce DNA damage and promote
cancer development [32, 36]. Over the past decade, much
attention has been paid on the role of cyclooxygenases in
cancer development, speciﬁcally its inducible isoform, the
cyclooxygenase 2 (COX-2) [39–41] .C O X - 2i sa c t i v ew i t h i n
bothinﬂamedandmalignanttissues[37–39].Theexpression
of COX-2 and COX-2 metabolites increases during the
multistage progression of tumors [39–41]. By metabolizing
arachidonic acid to prostaglandins, COX-2 induces cellular
resistance to apoptosis, modulation of cellular adhesion and
motility, promotion of angiogenesis, and immunosuppres-
sion [42–47]. Epidemiological data has implicated COX-2
in the pathogenesis of a number of epithelial malignancies,
especiallycolorectalcancer[48,49].Inhibitionoftheenzyme
with COX inhibitors is associated with a dramatic reduction
in the incidence, morbidity and mortality of colorectal
cancer [48–51]. Recent attention has also been focused on
the role of 5-LOX, 12-LOX, and 15-LOX in cancer [52–60].
In pancreatic cancer, activation of the 5-LOX and 12-LOX
pathways enhances cancer cell proliferation, while the 15-
LOX pathway is protective against cancer development [61–
64].
1.5. The5-lipoxygenase/leukotrieneB4 pathway
andcancer
Accumulating evidence suggests that the 5-LOX pathway has
profound inﬂuence on the development and progression
of human cancers [61–64]. 5-LOX is overexpressed in
pancreatic cancer tissues but is not expressed in normal
pancreatic ductal cells [65]. Furthermore, this pathway is
already up-regulated in pancreatic intraepithelial neoplasias
(PanINs), which are the precursor lesions of pancreatic
adenocarcinoma [66]. Blockade of 5-LOX activity inhibits
proliferation and induces apoptosis in pancreatic cancer
c e l l sb o t hi nv i t r oa n di nv i v o[ 67–69]. Pancreatic cancer
cells secrete LTB4 and LTB4 induces proliferation in these
cells [62]. Two G-protein-coupled LTB4 receptors (BLT1 and
BLT2) have been cloned and characterized. BLT1 and BLT2
are high- and low-aﬃnity LTB4 receptors, respectively, and
form a gene cluster in humans. Both BLT1 and BLT2 are
up-regulatedinpancreaticcancertissues,andexpressionwas4 PPAR Research
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Figure 3: Eﬀe c to faP P A R γ receptor antagonist, GW9662 on the
inhibition of proliferation induced by LY293111 in AsPC-1 human
pancreatic cancer cells after 24 hours of treatment. These cells
express both the PPARγ receptor and LTB4 (BLT1 and BLT2)
receptors. While GW9662 alone was able to signiﬁcantly increase
thymidine incorporation, it was not able to block the inhibitory
eﬀect of diﬀerent concentrations of LY293111.
seen in all of the tested pancreatic cancer cell lines [65, 70].
Aswithotherproteinsinthe5-LOX/LTB4 pathway,BLT1and
BLT2 are already up-regulated in pancreatic intraepithelial
neoplasias (PanIN lesions) which are the precursors of
pancreatic adenocarcinomas [70]. This suggests that they
may be valuable targets for chemoprevention.
1.6. PPARγ andpancreaticcancer
Peroxisome proliferator activated receptor-γ (PPARγ)i sa
member of the nuclear receptor superfamily of ligand-
activated transcription factors. PPARγ is expressed at high
levels in adipose tissue and plays a central role in adipocyte
diﬀerentiation and energy homeostasis. Recent studies have
implicated PPARγ in the pathogenesis of several human
malignancies [71–74]. Previous studies have suggested that
PPARγ is up-regulated in pancreatic cancer [75]. Our
own studies, employing two separate commercially available
antibodies, show that PPARγ is expressed in pancreatic
cancer,butthatexpressioninthecancercellsdoesnotappear
to be diﬀerent from that in normal pancreatic ductal cells
(Figure 1). In contrast, PPARγ staining was seen in the islets
surrounding cancers, but not in islet cells from normal pan-
creatic tissues obtained from multiorgan donors (Figure 1).
In animal models, PPARγ ligands have preventive eﬀects
against chemical carcinogenesis [76]. Several studies have
shown that PPARγ agonists, including the natural ligand
15-deoxy-Δ12,14-prostaglandin J2, and thiazolidinedione
antidiabetic agents, such as citiglitizone and rosiglitizone,
inhibit growth and induce apoptosis in pancreatic cancer
[75, 77–81]. In contrast, one paper suggests induction
of diﬀerentiation without apoptosis [82]. The apoptosis
appears to be preceded by a morphological change to a more
diﬀerentiated cell type which perhaps undergoes apoptosis
when DNA repair turns out to be not possible [80]. In some
studies,PPARγ agonistsalsoblockinvasionandangiogenesis
[83, 84]. However, this is controversial since PPARγ agonists
induce secretion of vascular endothelial growth factor, which
would have a promoting eﬀect on metastatic tumor growth
[85].
1.7. LY293111andcancer
As might be expected from the growth-stimulatory eﬀects
of LTB4 in pancreatic cancer, the LTB4 receptor antagonist,
LY293111 inhibits cancer growth and induces apoptosis both
in vitro and in vivo [86–89]. LY293111 inhibits proliferation
and induces apoptosis in a wide range of pancreatic cancer
cell lines as well as cells of other tumor types, such as
breast, prostate, and colon cancer cells [86–89]. These eﬀects
on growth and apoptosis are both time and concentration
dependent, with eﬀects seen at 100–500 nM in vitro [86, 87].
To conﬁrm the involvementof LTB4 receptors in mediating
the eﬀect of LY293111 on human pancreatic cancer cell
proliferation, another selective LTB4 receptor antagonist,
U75302 was used in comparison with a selective LTD4
antagonist, LY171883 [86]. U75302 inhibits the proliferation
of pancreatic cancer cells; but it is less potent than LY293111
as expected from the lower receptor aﬃnity of this drug
[28, 29, 90]. In contrast, the selective LTD4 antagonist,
LY171883 had no signiﬁcant eﬀect on pancreatic cancer cell
growth. LY293111 causes cell cycle arrest in the S phase
of the cell cycle with suppression of expression of cyclin
A, cyclin E, and cdk2. In parallel with growth inhibition,
LY293111 induced apoptosis in all cancer cell lines tested
[86,87].LY293111induceddramaticmorphologicalchanges
inhuman pancreatic cancer cells following a short period of
treatment [86, 87]. The treated cells became rounded and
exhibitedmembraneblebbing,chromatincondensation,and
nuclear fragmentation, ﬁnally they were detached from the
microplate. Induction of DNA fragmentation by LY293111
was conﬁrmed by TUNEL assay (terminal deoxynucleotidyl
transferase-mediated nick end labeling) and apoptosis was
also established by annexin V binding [86, 87]. Apoptosis
is triggered through the mitochondrial pathway, with a
change in the ratio of proapoptotic proteins, such as Bax to
antiapoptotic proteins, such as Bcl-2 and Mcl-1, release of
cytochrome C, activation of caspase (but not caspase 8), and
subsequent activation of the downstream caspase cascade
with activation of caspase 3 and caspase 7 and cleavage of
the caspase 3 substrate, poly ADP-ribose polymerase (PARP)
[87].
LY293111 markedly slows down the growth of subcu-
taneous xenografts of human pancreatic cancer in athymic
mice at a dose of 250mg/kg/day [86]. To conﬁrm the
antipancreatic cancer eﬀect of LY293111, pancreatic cancer
cells with stable expression of enhanced green ﬂuorescent
protein (GFP) were orthotopically implanted into the duo-
denal lobe of the pancreas of athymic mice. Our data
show that LY293111 signiﬁcantly inhibits the growth of the
orthotopically implanted pancreatic cancer cells in concert
with blocking metastatic spread to the liver and other organsThomas E. Adrian et al. 5
[91]. LY293111 also dramatically increased the number of
TUNEL positive cells in pancreatic tumors harvested from
the subcutaneous transplant experiments in athymic mice
[86, 91].
1.8. LY293111asaPPARγ agonist
Following the disclosure of anticancer eﬀects of LY293111,
researchers at the Lilly Research Laboratories found that
LY293111 is also a PPARγ agonist [92, 93]. This ﬁnding was
initially based on structural analysis and was supported by
functional studies. The PPARγ agonist activity of LY293111
isevidencedbyitsabilitytoinduceadipogenicdiﬀerentiation
in vitro [92]. Normalization of circulating glucose levels by
LY293111intheZDFratdiabetesmodelfurthersuggeststhat
LY293111 is an antidiabetic, PPARγ agonist [92]. Further
studies suggested that the anticancer eﬀect of LY293111
might be mediated, at least in part, by PPARγ [92, 93]. More
extensive studies have subsequently shown that LY293111 is
also an inhibitor of 5-lipoxygenase, although this eﬀectis less
potent than the LTB4 and PPARγ targets.
1.9. MechanismsbywhichLY293111
functionsincancer
Since our ﬁndings suggest that all pancreatic cancer cells
express both PPARγ and BLT1, it is possible that the
anticancer eﬀects of LY293111 could be mediated by either
receptor or both receptors. It has been reported that
PPARγ negative-expressing cancer cells are less responsive
to LY293111-induced growth inhibition [92, 93]. However,
there is also evidence in favor of BLT1 being the major target.
Firstly,theeﬀectsofLY293111onproliferationandapoptosis
are extremely potent. A comparison between the eﬀects of
LY293111 and the PPARγ agonist, ciglitazone is shown in
Figure 2. As this ﬁgure shows, LY293111 is approximately
50 times more potent than ciglitazone in inhibiting the
proliferation of Panc-1 and S2-013 human pancreatic cancer
cells. LY293111 was also more potent than another PPARγ
agonist, rosiglitazone and the PPARα agonist, WY-14643.
The antiproliferative eﬀects and induction of apoptosis are
seen at 250 nM LY293111, which is much lower than the IC50
of the drug for PPARγ receptors (∼4 μM) [92, 93]. Indeed,
its eﬀects on cancer cells are more potent than several PPARγ
agonists, including ciglitazone and rosiglitazone. Secondly,
LY293111 is able to completely inhibit the eﬀects of LTB4
on proliferation and MAP kinase activation in pancreatic
cancer cells [62]. However, preliminary studies have shown
that the antiproliferative eﬀects of LY293111 in pancreatic
cancer are not inhibited by the PPARγ antagonist, GW9662
in vitro (Figure 3). Finally, data from our own studies and
those of others show that PPARγ agonists induce cell cycle
arrestintheG0/G1phase,whereasLY293111inducesSphase
cell cycle arrest [82, 87]. It is even possible that anticancer
eﬀects of LY293111 might also be partially mediated by other
unknown mechanisms. However, based on the current data,
both the leukotriene B4 receptor and PPARγ are likely to be
involved in the antitumor activity of LY293111.
2. EFFECT OF LY293111 IN COMBINATION WITH
OTHER AGENTS IN CANCER
Several studies have demonstrated that LY293111 enhances
anticancer eﬀects of gemcitabine, which is widely used as the
standard therapy in pancreatic cancer patients in adjuvant
and palliative treatment settings [89, 91, 94]. Gemcitabine
only improves survival by a few weeks, but clinical data
show improvement in the quality of life for pancreatic
cancer patients. The eﬀects of LY293111 in combination
with gemcitabine were investigated in an orthotopic model
of pancreatic cancer in athymic mice [91]. This model is
superior to subcutaneous transplantation since it is less
likely to modify the biological characteristic of pancreatic
cancer cells, providing a favourable growth environment for
them. It also allows easy monitoring of hepatic and lymph
node metastasis with GFP stable expressing cells. In this
model, animals without any treatment following implan-
tation of GFP-expressing, S2-O13 pancreatic cancer cells
developed end-stage disease with invasive cancer obstructing
the duodenum and bile duct [91]. The animals develop liver,
lung, and lymph node metastases and eventually peritoneal
carcinomatosis with malignant ascites and cachexia [91].
Either gemcitabine or LY293111 alone signiﬁcantly inhibited
tumor growth and reduced the incidence of liver metastasis.
However the combination of LY293111 and gemcitabine
was signiﬁcantly more eﬀective than either treatment alone
in blocking tumor growth [91]. Combined treatment also
signiﬁcantly relieved tumor-induced cachexia and main-
tained stable body weights compared with either drug alone,
and also signiﬁcantly decreased the incidence of biliary
obstruction and metastasis [91]. These experimental results
show that combined therapy of gemcitabine and LY293111
potently inhibits the growth and metastases of the very
rapidly growing and aggressive pancreatic adenocarcinoma
and suggest that it might be a valuable way for treatment of
pancreatic cancer patients. LY293111 has also been shown to
increase the eﬀectiveness of gemcitabine in a colon cancer
model [89]. The in vitro eﬀects of LY293111 have been
tested with other classical chemotherapeutic agents. The
eﬀects of the active metabolite of irinotecan, SN-38 or the
active metabolite of capecitabine, 5 -DFUR were enhanced
by LY293111 in multiple cell lines, including breast, bladder,
and sarcoma cells [94].
3. CLINICAL TRIALS WITH LY293111
Three phase I clinical trials with LY293111 alone or in
combination with gemcitabine or irinotecan have been
reported. LY293111 was generally well tolerated [95–97].
The side eﬀects were mild to moderate; the major ones
gastrointestinal with diarrhea and pain. These initial phase
I trials looked promising and LY293111 could be safely
administered orally [95–97]. For example, in combination
with gemcitabine, three patients had partial responses [96].
One had pancreatic cancer previously treated with gemc-
itabine, one with pancreatic cancer previously treated with
5-ﬂurouracil and radiation, and one with non-small-cell
lung cancer treated with one prior regimen. Two phase II6 PPAR Research
trials have been completed and preliminary data reported
in abstract form [98, 99]. One of these compared the
combination of LY293111 with gemcitabine compared with
gemcitabine with placebo in pancreatic cancer [98]. The
second compared LY293111 with cisplatin and gemcitabine
versus the placebo combined with the latter two drugs in
patientswithnon-small-celllungcancer[99].Unfortunately,
LY293111didnotimproveprogression-freesurvivalineither
of these two trials [98, 99].
4. CONCLUSIONS
LY293111 is an interesting compound that has biological
eﬀects on several diﬀerent targets. It acts as an antag-
onist on LTB4 receptors, as a PPARγ agonist and as a
5-lipoxygenase inhibitor. Indeed, some investigators have
referred to LY293111 as a multiple eicosanoid pathway
inhibitor [94, 99]. Since LY293111 has anticancer eﬀects on
multiple tumor types, the target involved in mediating the
eﬀects of the drug is clearly of interest. The evidence to date
is not conclusive, but suggests that eﬀects may be mediated
by both LTB4 receptors and PPARγ. Preliminary reports
regarding the phase II clinical trials have unfortunately been
disappointing. It remains unknown whether this compound
will eventually ﬁnd a use in the clinic for cancer therapy;
however this recent clinical experience perhaps makes this
unlikely now.
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